Abstract
Abstract
It is frequently assumed, particularly in the last 15 plus years, that “Natural Product Structures” are no longer a source of drugs in the twenty-first century. In fact, this is not at all true. Even today, in the search for novel agents against manifold diseases, natural product structures, some quite old and some quite recent, are behind the compounds that are either recently (last 5–10 years) approved or that are now in clinical trials against manifold diseases of man. This chapter will cover agents approved since 2010 to the end of 2017 by the US FDA and its equivalent in other countries, plus selected agents that have entered clinical trials against major diseases such as cancer and infections that have “in their chemical pedigree” a natural product structure, even if the final product may be totally synthetic in nature.
Subject
General Physics and Astronomy,General Materials Science,General Chemistry
Reference98 articles.
1. Homoharringtonine/Omacetaxine Mepesuccinate: the long and winding road to food and drug administration approval;Clin Lymph Myel Leuk,2013
2. The ups and downs of drug discovery: the early history of Fidaxomicin;J Antibiot (Tokyo),2017
3. The ups and downs of drug discovery: the early history of Fidaxomicin;J Antibiot (Tokyo),2017
4. New semisynthetic glycopeptides MDL 63,246 and MDL 63,042, and other amide derivatives of antibiotic A-40,926 active against highly glycopeptide-resistant VanA enterococci;J Antibiot (Tokyo),1995
5. Optimization of homoharringtonine fermentation conditions for Alternaria tenuissima CH1307, an endophytical fungus of Cephalotaxus mannii Hook F;J Trop Med,2012
Cited by
18 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献